In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).
Researchers Identify New Role for Immune-Boosting Protein “STING” in Treatment of Head and Neck Cancer
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Researchers Identify Genes Behind Uterine Leiomyosarcoma Which May Be Treated Using Precision Medicine
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Cecelia Calhoun Named Director of the Adolescent-Young Adult Sickle Cell Program at Yale Cancer Center and Smilow Cancer Hospital
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
Yale Study Shows Combined Liver–Cytokine Humanization Rescues Circulating Red Blood Cells for Testing of Novel Therapeutics
In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.
In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer.
Maryam Lustberg Named Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).
In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences.
Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Following an extensive national search, Stephanie Halene, MD, PhD, has been appointed Chief of Hematology at Yale Cancer Center, Smilow Cancer Hospital and the Yale School of Medicine Department of Internal Medicine.
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.
The Connecticut Lions Eye Research Foundation has awarded a grant to Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center.
In a new study by Yale Cancer Center, scientists have identified the short endosomal protein interferon-inducible transmembrane protein 3 or IFITM3 as a central amplifier to supercharge activation of immune cells.
Dr. Michaela Dinan Named Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center
Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center.
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
The National Cancer Institute has awarded a UM1 grant renewal to Yale Cancer Center. The 6-year, $3 million a year grant will fund early phase investigator-initiated clinical trials to develop new potential therapies for treating both solid tumors and hematologic malignancies.
Dr. Marcella Nunez-Smith Named Director of Center for Community Engagement and Health Equity for Yale Cancer Center and Smilow Cancer Hospital
Marcella Nunez-Smith, MD, MHS, has been appointed Director of the Center for Community Engagement and Health Equity for Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH), as well as Chief Health Equity Officer & Deputy Chief Medical Officer, at SCH, and Associate Cancer Center Director for Community Outreach and Engagement at YCC.
Müschen Named Inaugural Director of Center of Molecular and Cellular Oncology at Yale Cancer Center and Yale School of Medicine
Markus Müschen, M.D., Ph.D., has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. Müschen will also be appointed Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology at Yale School of Medicine.
Yale Cancer Center researchers were awarded a $11 million grant renewal from the National institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer.
In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act (ACA) a higher percentage of women with breast cancer had their disease diagnosed at an early stage. No such change was seen in states that didn’t expand their coverage. The findings were published today in JAMA Surgery.
New findings led by Yale Cancer Center researchers and experts across several medical specialties at Yale identify a leading mechanism behind the pathophysiology of Covid-19 and pinpoint a biological marker for the mechanism that may aid in treating these patients.
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
Yale scientists develop a new experimental method to study infection and disease, including COVID-19
Yale Cancer Center scientists have developed a new cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called “traptamers” and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19. The data is published today in the journal Cell Reports.
Yale Cancer Center scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven “oncometabolites” may make cells more prone to developing cancer—but also more vulnerable to new cancer treatment strategies.
Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
The common belief that tumors arise via activation of a few genes that “drive” cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center (YCC) researchers.
Yale Cancer Center announces the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program.
A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance pancreatic cancer — and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.
First Test Using Immunotherapy Drug to Treat Advanced Lung Cancer Shows Benefit — And Future Promise
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.
There are substantial costs associated with breast cancer screenings for U.S. women in their 40s, a new Yale Cancer Center-led study finds, and these costs vary widely by region.
Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).
Raymond Lenox, APRN, was presented with the Yale Cancer Center Ruth McCorkle Oncology Advanced Practice Provider Award at YCC’s annual Conclave.
Qin Yan, Ph.D., was presented with the Yale Cancer Center (YCC) Class of 1961 Cancer Research Award at YCC’s annual Conclave
Yale Cancer Center (YCC) held its annual Conclave and award ceremony. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13.
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Sarah Mougalian, M.D., assistant professor of Medicine (Medical Oncology) has been named the inaugural Deputy Chief Ambulatory Officer at Smilow Cancer Hospital (SCH) at Yale New Haven Hospital.
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer
Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients
New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.
A new study by Yale Cancer Center (YCC) researchers shows understanding treatment patterns for patients with acute myeloid leukemia (AML) is vital to develop strategies to improve outcomes.